Clinical pharmacokinetics and pharmacodynamics of the epidermal growth factor receptor inhibitor panitumumab in the treatment of colorectal cancer
S Ketzer, K Schimmel, M Koopman… - Clinical …, 2018 - Springer
Despite progress in the treatment of metastatic colorectal cancer (mCRC) in the last 15
years, it is still a condition with a relatively low 5-year survival rate. Panitumumab, a fully …
years, it is still a condition with a relatively low 5-year survival rate. Panitumumab, a fully …
Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients
L Hamzehzadeh, F Khadangi, EG Karimiani… - Current Problems in …, 2018 - Elsevier
Objectives Mutation analysis of the Epidermal Growth Factor Receptor downstream has
been a main part of colorectal carcinoma evaluation. Large prospective clinical trials have …
been a main part of colorectal carcinoma evaluation. Large prospective clinical trials have …
Skin toxicity and quality of life during treatment with panitumumab for RAS wild-type metastatic colorectal carcinoma: results from three randomised clinical trials
R Koukakis, F Gatta, G Hechmati, S Siena - Quality of Life Research, 2016 - Springer
Purpose Epidermal growth factor receptor inhibitors such as panitumumab are associated
with characteristic skin toxicities. We summarise data from three panitumumab clinical trials …
with characteristic skin toxicities. We summarise data from three panitumumab clinical trials …
[HTML][HTML] Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial
Introduction Metastatic colorectal cancer is rarely curable. Improving quality of life is
therefore a key treatment goal. We report quality of life for patients with RAS wild-type …
therefore a key treatment goal. We report quality of life for patients with RAS wild-type …
Quality-Adjusted Survival in Patients with Recurrence of Breast Cancer Diagnosed by Asymptomatic or Symptomatic Opportunities
K Yamanouchi, S Maeda - The Kurume Medical Journal, 2022 - jstage.jst.go.jp
After radical surgery for breast cancer, screening to diagnose recurrence in asymptomatic
patients is not recommended. We retrospectively evaluated quality-adjusted survival …
patients is not recommended. We retrospectively evaluated quality-adjusted survival …
[PDF][PDF] Research and Reviews: Journal of Pharmaceutical Research and Clinical Practice
G Milano, MC Etienne-Grimaldi, L Llorca, P Formento… - Citeseer
We tested the predictive value of gene polymorphisms potentially linked to the
pharmacodynamics of panitumumab and irinotecan. Methods: 45 patients with metastatic …
pharmacodynamics of panitumumab and irinotecan. Methods: 45 patients with metastatic …
[PDF][PDF] ANALIZA EKONOMICZNA
PZPRJ GRUBEGO, OWG BRAF - bipold.aotm.gov.pl
ANALIZA EKONOMICZNA Page 1 ANALIZA EKONOMICZNA PANITUMUMAB (VECTIBIX®)
WI LINII LECZENIA DOROSŁYCH PACJENTÓW Z PRZERZUTOWYM RAKIEM JELITA …
WI LINII LECZENIA DOROSŁYCH PACJENTÓW Z PRZERZUTOWYM RAKIEM JELITA …